Press Releases
Page 7 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
Cumberland Pharmaceuticals Announces Strategic Integration with Apotex in Major Commercial Partnership Deal
Cumberland Pharmaceuticals (CPIX) enters strategic agreement with Apotex to integrate commercial operations, marking significant shift in specialty pharma landscape.
Tilray Brands Positioned for Major U.S. Medical Cannabis Expansion Following Historic Rescheduling
Tilray Brands leverages international medical cannabis expertise across 20+ countries to capitalize on U.S. market expansion opportunities amid cannabis rescheduling.
Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access
CCBD becomes first Maryland community oncology practice to offer FDA-approved CAR T-cell therapy, significantly expanding patient access in the region.
SamaCare Launches Industry-First Prior Authorization Performance Benchmarks for Medical Benefit Drugs
SamaCare introduces first-of-its-kind benchmarks tracking prior authorization approval rates and time to therapy across specialty practices nationwide.
Repertoire Immune Medicines Doses First Patient in RPTR-1-201 Phase 1/2 Trial for Advanced Solid Tumors
Repertoire Immune Medicines begins Phase 1/2 trial of RPTR-1-201, a novel TCR bispecific therapy targeting advanced solid tumors across US and European sites.
Alpha Tau Treats First Patient with Alpha DaRT in European Pancreatic Cancer Trial ACAPELLA
Alpha Tau initiates Alpha DaRT treatment in ACAPELLA trial for locally advanced pancreatic cancer, addressing unmet need for 42,000 European patients annually.
Alpha Tau Treats First European Pancreatic Cancer Patient with Alpha DaRT in ACAPELLA Clinical Trial
Alpha Tau successfully treats first European patient with Alpha DaRT radiotherapy in French ACAPELLA trial for locally advanced pancreatic cancer.
Healthcare Third-Party Logistics Market to Double by 2034, Reaching $502.6 Billion Driven by Pharmaceutical Growth
Healthcare 3PL market projected to grow from $246.1B to $502.6B by 2034 at 7.8% CAGR, driven by pharmaceutical expansion and cold chain logistics demand.
Pharmaceutical Intermediates Market to Reach $57 Billion by 2035 as Generic Drug Manufacturing Drives 4.5% Annual Growth
Global pharmaceutical intermediates market projected to grow from $36.62B to $57.03B by 2035, driven by generic drug demand and advanced manufacturing.
Belite Bio Submits New Drug Application for Tinlarebant to Treat Stargardt Disease Following Positive Phase 3 Results
Belite Bio initiates rolling NDA submission for tinlarebant after Phase 3 DRAGON trial showed 35.7% reduction in retinal lesion growth for Stargardt disease patients.
Abivax Presents Obefazimod Phase 3 Data at Digestive Disease Week 2026
Abivax showcases comprehensive Phase 3 ABTECT program results for obefazimod in inflammatory bowel disease at DDW 2026 conference.
Pet Service Holding Reports 2025 Annual Results Amid European Veterinary Regulatory Changes
Pet Service Holding NV announces 2025 annual results showing strategic transition while navigating evolving European veterinary medicine regulations.